Micafungin as primary antifungal prophylaxis in patients presenting withacute myeloid leukemia

Abstract : Objective. – To study the efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing inductionchemotherapy for acute myeloid leukemia.Patients and methods. – A prospective observational single-center study of 41 patients from the hematology department between May 2012 andApril 2015. Micafungin was administered once daily from the first day of induction chemotherapy to the end of the neutropenic phase.Results. – Neither Candida nor Aspergillus infection was documented in our 41 patients from the first day of micafungin infusion to the end ofthe neutropenic phase. Patients were followed for three months after discontinuation of micafungin and none of them contracted an invasive fungalinfection. Only one patient presented with grade III–IV hepatic and ionic toxicities.Conclusion. – Micafungin is associated with a good safety profile and is an interesting option for preventing invasive fungal infections in thehigh-risk population of patients presenting with hematological disorders.
Type de document :
Article dans une revue
Médecine et Maladies Infectieuses, Elsevier Masson, 2016, [Epub ahead of print]. 〈10.1016/j.medmal.2016.03.008〉
Liste complète des métadonnées

Littérature citée [16 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-01310711
Contributeur : Regis Costello <>
Soumis le : mardi 3 mai 2016 - 09:46:55
Dernière modification le : lundi 29 janvier 2018 - 17:30:06
Document(s) archivé(s) le : mardi 24 mai 2016 - 18:16:11

Fichier

 Accès restreint
Fichier visible le : jamais

Connectez-vous pour demander l'accès au fichier

Identifiants

Collections

Citation

Geoffroy Venton, Hélène Adam, J Colle, Yasmine Labiad, Cédric Mercier, et al.. Micafungin as primary antifungal prophylaxis in patients presenting withacute myeloid leukemia. Médecine et Maladies Infectieuses, Elsevier Masson, 2016, [Epub ahead of print]. 〈10.1016/j.medmal.2016.03.008〉. 〈inserm-01310711〉

Partager

Métriques

Consultations de la notice

132